Survival was significantly improved in patients with greater disease burden.
The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
Guideline-directed care resulted in equivalent outcomes independent of hospital setting.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.